Wegovy Not Suppressing Appetite? Here's What's Actually Going On

The biggest misconception: Wegovy should be working from the first pen

A lot of people expect the appetite-reducing effect to land within days of their first injection. It doesn't, and the assumption that it should is the source of most of the disappointment our prescribers hear about. The early doses in the Wegovy schedule (0.25mg, then 0.5mg) are primarily there to help your body adjust. At those levels, gastric side effects tend to take centre stage, and the appetite signal the medicine produces at higher maintenance doses is modest at best. Expecting 0.25mg to feel like 2.4mg is a bit like expecting a half-charged battery to run a full device.

The NHS semaglutide medicines page makes clear that the dose is titrated upwards over several months, and that the full clinical effect develops across that period. If you're in the first eight to twelve weeks of treatment, the answer to "why isn't Wegovy suppressing my appetite" is almost always: it isn't at that dose yet, and our page on when semaglutide starts suppressing appetite explains exactly how that timeline tends to unfold. Patience and consistency matter more at this stage than any adjustment.

This is also why the trial evidence (including the STEP 1 study published in the New England Journal of Medicine, which reported around 15% average weight reduction over 68 weeks) was measured at the 2.4mg maintenance dose, not the starting one. The outcomes reflect the full schedule, not the first few weeks.

Practical factors that quietly blunt the signal

Even at a dose where semaglutide is genuinely working, certain habits can make the appetite-suppressing effect almost invisible. High-fat, high-sugar foods are absorbed in ways that partly sidestep the gastric-slowing mechanism, which is part of why people sometimes notice they can still eat a surprising amount of calorie-dense processed food despite being on treatment. The fullness signal works best when meals contain protein and fibre, which interact differently with the digestive tract.

Alcohol is another common culprit. It stimulates appetite independently of GLP-1 pathways and can override the reduced-hunger signal almost entirely. Stress and poor sleep raise ghrelin, the hunger hormone, in ways that semaglutide doesn't directly counter. Dehydration is frequently mistaken for hunger too, a glass of water before reaching that conclusion is a useful first test.

For practical guidance on eating patterns that work alongside treatment, our page on what to eat on Wegovy covers the food choices that tend to make a real difference. Getting this right doesn't require a rigid diet, it's mostly about the composition of meals rather than strict rules.

The injection site and technique also matter more than people expect. Injecting into an area of scar tissue or with a needle that hasn't been changed consistently can affect absorption, and if you find Wegovy isn't suppressing your appetite at all, technique and timing are among the first practical things worth reviewing alongside your prescriber. Our Wegovy overview covers technique basics.

When appetite suppression fades after it was working well

This is a genuinely different situation from never feeling the effect in the first place, and it's worth naming separately. Some people notice a clear reduction in hunger for several weeks, then find it creeping back. This can happen for a few reasons: the body adapts somewhat to a stable dose over time; weight loss itself changes the hormonal environment in ways that can increase hunger signals; and occasionally a missed or delayed injection breaks the steady-state concentration that produces consistent appetite suppression.

If semaglutide is no longer suppressing your appetite after a period when it was, the first thing to check is injection timing. Semaglutide has a long half-life, so one slightly late dose is unlikely to cause a sharp return of hunger, but a pattern of variable timing adds up. A separate page on Wegovy appetite suppression fading over time goes into this in more detail, including the question of whether a dose review is appropriate.

If you're weighing up how the two main injectable options compare on appetite effect, there's also a broader discussion of weight-loss treatment options that puts the evidence side by side.

When to raise it with your prescriber

Most of what's described above resolves with time, consistency and small practical adjustments. But not everyone responds equally to GLP-1 receptor agonists, and a minority of people genuinely experience weaker appetite suppression even at maintenance doses, something we explore in more depth on our page about how Wegovy suppresses appetite and what influences the strength of that effect. This isn't a personal failing, it's biology, and it's exactly the kind of thing a clinical review is for.

Signs it's worth getting in touch: you've been on a stable maintenance dose for eight or more weeks and there's been no noticeable reduction in hunger; appetite suppression that was present has disappeared and hasn't returned despite consistent injections and no major lifestyle changes; or you're losing very little weight despite genuine adherence. The MHRA monitors the real-world safety and effectiveness of medicines like semaglutide, and your prescriber can draw on that evidence base alongside your individual history when reviewing the plan.

At nume (sorry, at nume) every repeat order goes through a fresh clinical review before anything is dispensed. Your pen arrives via DPD the next working day in plain, unbranded packaging, but the more important thing is what happens before it's sent: a real prescriber reads your answers, not a queue of automated checks. If appetite suppression is your concern, that review is the right place to raise it. Speak to our prescribers through a free consultation if you'd like a clinical view on where you are in treatment.